Molecular perspective on targeted therapy in breast cancer: a review of current status
Busra Demir Cetinkaya1, Cigir Biray Avci2
1Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan, Turkey.
Abstract:
Breast cancer is categorized at the molecular level according to the status of certain hormone and growth factor receptors, and this classification forms the basis of current diagnosis and treatment. The development of resistance to treatment and recurrence of the disease have led researchers to develop new therapies. In recent years, most of the research in the field of oncology has focused on the development of targeted therapies, which are treatment methods developed directly against molecular abnormalities. Promising advances have been made in clinical trials investigating the effect of these new treatment modalities and their combinations with existing therapeutic treatments in the treatment of breast cancer. Monoclonal antibodies, tyrosine kinase inhibitors, antibody-drug conjugates, PI3K/Akt/mTOR pathway inhibitors, cyclin-dependent kinase 4/6 inhibitors, anti-angiogenic drugs, PARP inhibitors are among the targeted therapies used in breast cancer treatment. In this review, we aim to present a molecular view of recently approved target agents used in breast cancer.
Insights
This review explores targeted therapies for breast cancer, focusing on novel agents like monoclonal antibodies and kinase inhibitors. These advanced treatments offer new hope against treatment resistance and disease recurrence.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Breast cancer classification relies on hormone and growth factor receptor status.
- Treatment resistance and recurrence necessitate novel therapeutic strategies.
- Oncology research increasingly focuses on targeted therapies against molecular abnormalities.
Purpose of the Study:
- To provide a molecular perspective on recently approved targeted agents for breast cancer.
- To review the landscape of advanced targeted therapies in breast cancer treatment.
Main Methods:
- Review of recent clinical trials and approved targeted agents.
- Analysis of molecular mechanisms underlying targeted therapy efficacy.
- Synthesis of data on targeted therapies including monoclonal antibodies, tyrosine kinase inhibitors, and others.
Main Results:
- Significant advances have been made in targeted therapy development for breast cancer.
- Combinations of targeted therapies with existing treatments show promise.
- Various targeted agents including monoclonal antibodies, tyrosine kinase inhibitors, and PI3K/Akt/mTOR pathway inhibitors are utilized.
Conclusions:
- Targeted therapies represent a significant advancement in breast cancer treatment.
- These agents offer new avenues for managing treatment resistance and recurrence.
- Continued research into molecular targets and drug combinations is crucial for improving patient outcomes.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:38Mitogens and the Cell Cycle
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...